wire - news in brief



Results 151 - 200 of 1656.

Health - Pharmacology - 11.12.2020
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number

Health - Pharmacology - 09.12.2020
Novartis Kisqali demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with un rivaled OS evidence 1 Kisqali plus endocrine therapy had a median OS of nearly five years (58&peri

Health - Pharmacology - 09.12.2020
Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine tri

Research Management - Pharmacology - 09.12.2020

Pharmacology - Health - 08.12.2020
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif * in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibito

Pharmacology - Health - 08.12.2020
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers
Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, an

Pharmacology - Health - 05.12.2020
Novartis analyses confirm benefit of Kymriah with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83% 1 L

Pharmacology - Health - 04.12.2020
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic

Health - Pharmacology - 02.12.2020
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identif

Health - Pharmacology - 30.11.2020
Taco mattresses take the pressure off hospitals
Taco mattresses take the pressure off hospitals
During the lockdown last spring, Julian Ferchow put his doctoral project aside to help relieve the strain on hospitals.

Health - Pharmacology - 25.11.2020
Infusion more effective than tablets: Treatment of iron anaemia in rural Africa
Infusion more effective than tablets: Treatment of iron anaemia in rural Africa
Iron-deficiency anaemia is a major concern in low income countries, especially for women. A study conducted in Tanzania has now demonstrated the advantage of iron infusion therapy over the usual treatment with iron tablets.

Health - Pharmacology - 25.11.2020
Tackling pandemic threats proactively
If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.

Health - Pharmacology - 18.11.2020
Coronavirus: simplified, faster generation of SwissCovid app codes
The process of generating covidcodes has been significantly simplified and accelerated. Persons who have tested positive can enter their code into the SwissCovid app to inform other app users of possible exposure to the virus.

Pharmacology - Health - 13.11.2020
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult p

Pharmacology - Health - 13.11.2020
Results from real-world data and post-hoc analysis of Novartis Beovu pivotal trials presented at AAO 2020
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commi

Health - Pharmacology - 06.11.2020
Novartis provides update on CAN-COVID trial in hospitalized patients
The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilatio

Pharmacology - Health - 05.11.2020
Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx at Week 12 vs.

Health - Pharmacology - 30.10.2020
Contact tracing with prophylactic treatment could near-eliminate leprosy
Contact tracing with prophylactic treatment could near-eliminate leprosy
Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programmes, and is generally well accepted by patients, their contacts, and healthcare workers.

Pharmacology - Health - 29.10.2020
Novartis presents latest Phase III data reinforcing Cosentyx as a first-line systemic treatment in pediatric psoriasis
Latest data show Cosentyx provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile 1,2 Moderate-to-severe psoriasis affects more than 350,0

Health - Pharmacology - 29.10.2020
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
Acquisition expands the Novartis footprint in ophthalmology and enhances the company's position as an AAV-based gene therapy powerhouse.

Pharmacology - 22.10.2020

Health - Pharmacology - 13.10.2020
Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry analys

Pharmacology - Health - 05.10.2020
New Phase III analysis demonstrates Novartis Beovu showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
In a post-hoc analysis of HAWK and HARRIER , fewer Beovu (brolucizumab ) patients had early persistent fluid (12 .5% vs.

Pharmacology - Health - 01.10.2020
Zolgensma data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10&

Pharmacology - Health - 23.09.2020
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (I T) formulation in older patients with SMA to further support registration Basel, Septembe

Health - Pharmacology - 21.09.2020
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score - confirming substantial benefit for premenopausal women with HR+/HER2- advanced bre

Health - Pharmacology - 18.09.2020
Patches to detect when a viral disease is about to get worse
Xsensio, an EPFL spin-off, has just been awarded CHF 1.8 million in EU funding to adapt its Lab-on-Skin(TM) sensing patches so that they can detect when a viral illness like the flu or COVID-19 is about to get worse.